HUT66829A - Analogs of piscine lhrh - Google Patents
Analogs of piscine lhrh Download PDFInfo
- Publication number
- HUT66829A HUT66829A HU9301979A HU9301979A HUT66829A HU T66829 A HUT66829 A HU T66829A HU 9301979 A HU9301979 A HU 9301979A HU 9301979 A HU9301979 A HU 9301979A HU T66829 A HUT66829 A HU T66829A
- Authority
- HU
- Hungary
- Prior art keywords
- amino acid
- fish
- gly
- analog
- antibody
- Prior art date
Links
- 241000251468 Actinopterygii Species 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 41
- 125000000539 amino acid group Chemical group 0.000 claims description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims description 21
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 19
- 229960005486 vaccine Drugs 0.000 claims description 18
- 230000003053 immunization Effects 0.000 claims description 16
- 230000008569 process Effects 0.000 claims description 16
- 238000002649 immunization Methods 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 10
- 230000035800 maturation Effects 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 230000036301 sexual development Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 230000035938 sexual maturation Effects 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 150000008574 D-amino acids Chemical group 0.000 claims description 4
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 4
- 238000001514 detection method Methods 0.000 claims description 2
- 239000000700 radioactive tracer Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000010170 biological method Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000010188 recombinant method Methods 0.000 claims 1
- 235000019688 fish Nutrition 0.000 description 70
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 16
- 241000277275 Oncorhynchus mykiss Species 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 208000026487 Triploidy Diseases 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 241000277331 Salmonidae Species 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 241000972773 Aulopiformes Species 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000002516 postimmunization Effects 0.000 description 7
- 235000019515 salmon Nutrition 0.000 description 7
- 150000003431 steroids Chemical class 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 229940098773 bovine serum albumin Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000001568 sexual effect Effects 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- -1 His Chemical compound 0.000 description 5
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- 241000157468 Reinhardtius hippoglossoides Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000002920 convulsive effect Effects 0.000 description 4
- 229960005309 estradiol Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000003306 harvesting Methods 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000005070 ripening Effects 0.000 description 4
- WTPMRQZHJLJSBO-XQALERBDSA-N 11-oxotestosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 WTPMRQZHJLJSBO-XQALERBDSA-N 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 230000035558 fertility Effects 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000002149 gonad Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 2
- 241000607525 Aeromonas salmonicida Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 241000277263 Salmo Species 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010047400 Vibrio infections Diseases 0.000 description 2
- 241001135139 Vibrio ordalii Species 0.000 description 2
- 241001148129 Yersinia ruckeri Species 0.000 description 2
- JGGWZMZAZCBABX-UHFFFAOYSA-N [1-(2,5-dioxopyrrol-1-yl)-2,5-dioxopyrrolidin-3-yl] butanoate Chemical compound O=C1C(OC(=O)CCC)CC(=O)N1N1C(=O)C=CC1=O JGGWZMZAZCBABX-UHFFFAOYSA-N 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 229960003983 diphtheria toxoid Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 208000003512 furunculosis Diseases 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000009372 pisciculture Methods 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 229960001005 tuberculin Drugs 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 description 1
- WIGPSBHTJZUPKU-UHFFFAOYSA-N 3-benzoyl-1-hydroxypyrrolidine-2,5-dione Chemical compound O=C1N(O)C(=O)CC1C(=O)C1=CC=CC=C1 WIGPSBHTJZUPKU-UHFFFAOYSA-N 0.000 description 1
- ZLANMTTYEJHZIE-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)benzenediazonium Chemical compound O=C1C=CC(=O)N1C1=CC=C([N+]#N)C=C1 ZLANMTTYEJHZIE-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 241001519451 Abramis brama Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 238000012375 Ion exchange chromatography - high performance liquid chromatography Methods 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000612182 Rexea solandri Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 239000003668 hormone analog Substances 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 230000036417 physical growth Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 229940070741 purified protein derivative of tuberculin Drugs 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Circuits Of Receivers In General (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919100468A GB9100468D0 (en) | 1991-01-09 | 1991-01-09 | Improvements in and relating to hormones |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HU9301979D0 HU9301979D0 (en) | 1993-11-29 |
| HUT66829A true HUT66829A (en) | 1995-01-30 |
Family
ID=10688207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9301979A HUT66829A (en) | 1991-01-09 | 1992-01-08 | Analogs of piscine lhrh |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP0566611A1 (ja) |
| JP (1) | JPH06504537A (ja) |
| KR (1) | KR930703444A (ja) |
| CN (1) | CN1063109A (ja) |
| AU (1) | AU652611B2 (ja) |
| CA (1) | CA2100057A1 (ja) |
| DK (1) | DK80993A (ja) |
| FI (1) | FI933138A0 (ja) |
| GB (2) | GB9100468D0 (ja) |
| HU (1) | HUT66829A (ja) |
| IE (1) | IE920055A1 (ja) |
| IS (1) | IS3802A (ja) |
| NO (1) | NO932491D0 (ja) |
| NZ (1) | NZ241240A (ja) |
| PT (1) | PT99991A (ja) |
| WO (1) | WO1992012247A1 (ja) |
| ZW (1) | ZW392A1 (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9306984A (pt) | 1992-08-27 | 1999-01-12 | Deakin Res Ltd | Análogo de antígeno de peptídeo de um antígeno de peptídeo nativo vacina anticorpo processo para vacinar um hospedeiro necessitando deste tratamento estojo diagnóstico processos para preparar um análogo de um antiígeno de um antígeno de peptídeo nativo para preparar uma vacina para analisar uma amostra para um antígeno de peptídeo nativo e para analisar uma amostra para um anticorpo |
| US5688506A (en) * | 1994-01-27 | 1997-11-18 | Aphton Corp. | Immunogens against gonadotropin releasing hormone |
| US5760000A (en) * | 1994-05-13 | 1998-06-02 | University Technologies International,Inc. | Inhibition of liver cancer by the use of GnRH and GnRH analogs |
| EP1140151A2 (en) * | 1998-12-22 | 2001-10-10 | Dalhousie University | Compositions and methods for reducing or preventing fertilization in fish and birds |
| GB0226179D0 (en) | 2002-11-09 | 2002-12-18 | Millar Robert P | Vaccine |
| NO20075894L (no) * | 2007-11-15 | 2009-05-18 | Thia Medica As | Redusert kjonnsmodning i fisk |
| JP6909160B2 (ja) * | 2015-11-27 | 2021-07-28 | 日本水産株式会社 | 細胞膜透過性ペプチド及び細胞膜透過性ペプチドを用いた魚類飼料 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443368A (en) * | 1982-11-01 | 1984-04-17 | The Salk Institute For Biological Studies | Peptides affecting gonadal function |
| US4410514A (en) * | 1982-12-06 | 1983-10-18 | The Salk Institute For Biological Studies | GnRH Agonists |
| US4608251A (en) * | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
| GB8713240D0 (en) * | 1987-06-05 | 1987-07-08 | Proteus Biotech Ltd | Hormones |
| JPH06509075A (ja) * | 1991-07-01 | 1994-10-13 | ユニヴァーシティ テクノロジーズ インターナショナル インコーポレイテッド | ＧｎＲＨ及び他の生物学的に活性なリガンドの非感度低下性類縁体 |
-
1991
- 1991-01-09 GB GB919100468A patent/GB9100468D0/en active Pending
-
1992
- 1992-01-07 NZ NZ241240A patent/NZ241240A/xx unknown
- 1992-01-08 HU HU9301979A patent/HUT66829A/hu unknown
- 1992-01-08 WO PCT/GB1992/000040 patent/WO1992012247A1/en not_active Application Discontinuation
- 1992-01-08 KR KR1019930702060A patent/KR930703444A/ko not_active Application Discontinuation
- 1992-01-08 AU AU11617/92A patent/AU652611B2/en not_active Ceased
- 1992-01-08 JP JP4502565A patent/JPH06504537A/ja active Pending
- 1992-01-08 EP EP92902189A patent/EP0566611A1/en not_active Withdrawn
- 1992-01-08 IS IS3802A patent/IS3802A/is unknown
- 1992-01-08 PT PT99991A patent/PT99991A/pt not_active Application Discontinuation
- 1992-01-08 CA CA002100057A patent/CA2100057A1/en not_active Abandoned
- 1992-01-08 IE IE005592A patent/IE920055A1/en not_active Application Discontinuation
- 1992-01-09 ZW ZW3/92A patent/ZW392A1/xx unknown
- 1992-01-09 CN CN92100141A patent/CN1063109A/zh active Pending
-
1993
- 1993-07-06 DK DK080993A patent/DK80993A/da not_active Application Discontinuation
- 1993-07-08 NO NO932491A patent/NO932491D0/no unknown
- 1993-07-08 FI FI933138A patent/FI933138A0/fi not_active Application Discontinuation
- 1993-07-08 GB GB9314141A patent/GB2267496B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| GB2267496B (en) | 1994-09-07 |
| IS3802A (is) | 1992-07-10 |
| GB2267496A (en) | 1993-12-08 |
| ZW392A1 (en) | 1992-07-22 |
| FI933138A (fi) | 1993-07-08 |
| KR930703444A (ko) | 1993-11-30 |
| AU1161792A (en) | 1992-08-17 |
| EP0566611A1 (en) | 1993-10-27 |
| CA2100057A1 (en) | 1992-07-10 |
| CN1063109A (zh) | 1992-07-29 |
| NO932491L (no) | 1993-07-08 |
| JPH06504537A (ja) | 1994-05-26 |
| HU9301979D0 (en) | 1993-11-29 |
| WO1992012247A1 (en) | 1992-07-23 |
| IE920055A1 (en) | 1992-07-15 |
| GB9100468D0 (en) | 1991-02-20 |
| AU652611B2 (en) | 1994-09-01 |
| NO932491D0 (no) | 1993-07-08 |
| DK80993D0 (da) | 1993-07-06 |
| GB9314141D0 (en) | 1993-09-22 |
| DK80993A (da) | 1993-07-06 |
| FI933138A0 (fi) | 1993-07-08 |
| PT99991A (pt) | 1993-01-29 |
| NZ241240A (en) | 1992-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0093652B1 (fr) | Toxine synthétique ST, son procédé de préparation et son application comme agent vaccinant | |
| TWI225069B (en) | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides | |
| RU2078770C1 (ru) | Производные пептидов и композиция, вызывающая иммунный ответ на lhrh | |
| EP0567512A1 (en) | Sperm cell surface protein ph-20. use in a contraceptive vaccine | |
| JPH08504090A (ja) | 抗−ネコ免疫不全ウイルス（ｆｉｖ）ワクチン | |
| KR100335320B1 (ko) | 황체호르몬방출호르몬에대한향상된펩티드,면역원성조성물및백신또는의학용제제,동물을면역시키는방법,및황체호르몬방출호르몬직렬반복펩티드의유사체및백신으로서이들의용도 | |
| HUT66829A (en) | Analogs of piscine lhrh | |
| CN107073086B (zh) | 免疫性lhrh组合物及其在猪只中的应用 | |
| EP0450715B1 (en) | Immunogenic compounds, the process for their synthesis and their use in the preparation of antimalaria vaccines | |
| EP0323769B1 (fr) | Structures peptidiques, immunogènes les contenant et leurs applications au contrôle de la fertilité | |
| WO1989000166A2 (en) | Growth hormone related peptide | |
| US20060188513A1 (en) | Novel inhibin-related multiple antigenic peptide compositions that enhance production performance in avians | |
| ES2280402T3 (es) | Discriminacion entre gnrh-i y gnrh-ii. | |
| US4578219A (en) | Antigenic peptide compound | |
| WO2014118318A1 (fr) | Composés agonistes du récepteur kiss1 et leur utilisation pour induire l'ovulation chez les mammifères | |
| JP2002518033A (ja) | 農場動物の成長促進のための合成ソマトスタチン免疫原 | |
| FR2532850A1 (fr) | Conjugues immunogenes entre un haptene et une molecule porteuse derivee d'une toxine, les vaccins les composant et procede pour leur obtention | |
| HU210966B (en) | Method for the preparation of peptides and veterinary compositions containing them | |
| EP0088752B1 (en) | Antigenic peptide compound | |
| FR2551088A1 (ja) | ||
| CS272790A2 (en) | Peptides with biological effect | |
| CA2389196A1 (en) | Cyclic peptides and aids vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DFD9 | Temporary protection cancelled due to non-payment of fee |